Worldwide incidence, molecular epidemiology and mutations implicated in fluoroquinolone-resistant Streptococcus pneumoniae:: data from the global PROTEKT surveillance programme

被引:98
作者
Canton, R
Morosini, M
Enright, MC
Morrissey, I
机构
[1] GR Micro Ltd, London NW1 3ER, England
[2] Univ Bath, Bath BA2 7AY, Avon, England
[3] Hosp Ramon & Cajal, E-28034 Madrid, Spain
关键词
multilocus sequence typing; Spain(23F)-1; topoisomerase mutations; fluoroquinolone resistance;
D O I
10.1093/jac/dkg465
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objectives: To analyse the mutations and epidemiology associated with fluoroquinolone-resistant pneumococci collected as part of the PROTEKT global surveillance programme during 1999-2000. Methods: Sixty-nine centres in 25 countries submitted a total of 3362 Streptococcus pneumoniae isolates, for which the MICs of antimicrobial agents were determined using NCCLS methodology. Results: Levofloxacin resistance was low overall (1% worldwide), with higher rates in: Hong Kong (14.3%), South Korea (2.9%), USA (1.8%), Mexico (1.5%), Canada (1.4%) and Japan (1.3%). Levofloxacin resistance was very low or absent in European countries, and absent in Australia. Worldwide, there was a total of 35 levofloxacin-resistant isolates, of which 22 (63%) were resistant and 10 (29%) were intermediate to moxifloxacin. All levofloxacin-resistant isolates were susceptible to telithromycin (less than or equal to0.5 mg/L), linezolid (less than or equal to2 mg/L) and quinupristin/dalfopristin (less than or equal to1 mg/L). One or more mutations in the topoisomerase genes were identified in all levofloxacin-resistant isolates; most of these isolates (33/35) had a mutation in one of the DNA gyrase encoding genes (gyrA, gyrB) and one of the topoisomerase IV encoding genes (parC, parE). Eighteen (51%) isolates carried the same combination of amino acid substitutions: Ser-81-->Phe in GyrA and Ser-79-->Phe in ParC. Isolates displaying a levofloxacin MIC of 2-4 mg/L generally had no mutation or one mutation in either a DNA gyrase or a topoisomerase IV gene, although most mutations were in parC. Conclusions: Most levofloxacin-resistant isolates possess two mutations (one in DNA gyrase and one in topoisomerase IV). Although multilocus sequence typing demonstrated that most of these isolates were unrelated, 12 (34%) were the Spain(23F)-1 clone: 10 from Hong Kong and one each from Saskatchewan, Canada and Sao Paulo, Brazil.
引用
收藏
页码:944 / 952
页数:9
相关论文
共 39 条
  • [1] New fluoroquinolones: Real and potential roles
    Peter Ball
    [J]. Current Infectious Disease Reports, 1999, 1 (5) : 470 - 479
  • [2] Ball P, 1998, Expert Opin Investig Drugs, V7, P761, DOI 10.1517/13543784.7.5.761
  • [3] Antimicrobial resistance of 1,113 Streptococcus pneumoniae isolates from patients with respiratory tract infections in Spain:: Results of a 1-year (1996-1997) multicenter surveillance study
    Baquero, F
    García-Rodríguez, JA
    de Lomas, JG
    Aguilar, L
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (02) : 357 - 359
  • [4] RAPID DEVELOPMENT OF CIPROFLOXACIN RESISTANCE IN METHICILLIN-SUSCEPTIBLE AND METHICILLIN-RESISTANT STAPHYLOCOCCUS-AUREUS
    BLUMBERG, HM
    RIMLAND, D
    CARROLL, DJ
    TERRY, P
    WACHSMUTH, IK
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1991, 163 (06) : 1279 - 1285
  • [5] Fluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994-1995
    Brueggemann, AB
    Coffman, SL
    Rhomberg, P
    Huynh, H
    Almer, L
    Nilius, A
    Flamm, R
    Doern, GV
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (03) : 680 - 688
  • [6] Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada
    Chen, DK
    McGeer, A
    de Azavedo, JC
    Low, DE
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (04) : 233 - 239
  • [7] FLUOROQUINOLONES IN CHRONIC OBSTRUCTIVE PULMONARY-DISEASE
    COLVILLE, A
    KNOWLES, M
    LARGE, D
    GEORGE, J
    MUSTCHIN, P
    [J]. BRITISH MEDICAL JOURNAL, 1994, 308 (6941) : 1437 - 1437
  • [8] Brief report: Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia.
    Davidson, R
    Cavalcanti, R
    Brunton, JL
    Bast, DJ
    de Azavedo, JCS
    Kibsey, P
    Fleming, C
    Low, DE
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (10) : 747 - 750
  • [9] DOEM GV, 1998, DIAGNOSTIC MICROBIOL, V32, P313
  • [10] Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance rates since 1994-1995
    Doern, GV
    Heilmann, KP
    Huynh, HK
    Rhomberg, PR
    Coffman, SL
    Brueggemann, AB
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (06) : 1721 - 1729